Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Nifurtimox PK in Chronic Chagas' Disease
NCT02606864Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nifurtimox in American trypanosomiasis (CD) (2 arms), sponsored by Bayer. Primary endpoints: Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point, Maximum plasma concentration and 2 more. Started Dec 2015; status: completed.
02
Drugs
nifurtimox
03
Conditions
American trypanosomiasis (CD)
Beyond the preview
Go deeper on NCT02606864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606864.